Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Inclusion Criteria: * 18 years of age or older * Diagnosis of vitiligo * Clinically stable vitiligo: defined as no new vitiligo patches and no enlargement of existing patches in previous 3 months. * Able to provide voluntary, written, informed consent Exclusion Criteria: * Clinically active vitiligo: defined as new vitiligo patches or enlargement of existing patches in previous 3 months * Concurrent skin disease in the study area * Immunocompromise * Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose.